AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion

barbara.lempert AMAG Pharmaceuticals Announces Submission of a Type II Variation for Rienso Label Expansion in Europe to Include All Adult Iron Deficiency Anemia Patients Who Cannot ...

Aeterna Zentaris Announces Dismissal of Class Action Lawsuit

barbara.lempert QUEBEC CITY, June 6, 2013 /CNW Telbec/ – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”), announced today that the previously disclosed ...

China Botanic Pharmaceutical Inc. Announces Withdrawal Of Request For Hearing

barbara.lempert HARBIN, China, June 7, 2013 /PRNewswire/ — China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) (“China Botanic” ...

AMRI Announces Appointment of William Marth as Chairman of the Board of Directors

barbara.lempert ALBANY, N.Y., June 5, 2013 /PRNewswire/ — AMRI (NASDAQ: AMRI), a leading global contract research and manufacturing organization, has announced that the Board ...

ZIOPHARM Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study

barbara.lempert ZIOPHARM Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study in Advanced Melanoma at the 2013 ASCO Annual Meeting BOSTON, June 1, 2013 (GLOBE ...

Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786

barbara.lempert Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA Expedited Development Path will Allow ...

Medigene announces capital reduction and nomination of new members to a reduced Supervisory Board

barbara.lempert •    Reduction of share capital by consolidation of shares by a ratio of 4:1 •    Measure increases the company’s transaction capacity   Martinsried/Munich, ...

Generex Announces ASCO Presentations of AE37 Vaccine Data

barbara.lempert Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients Treatment Regimen Targets All HER2 Expressing ...

Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib

barbara.lempert Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting ...

PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes

barbara.lempert INCLINE VILLAGE, Nev., June 3, 2013 /PRNewswire/ — PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% ...

Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib

mia.burns Synta Announces Positive Overall Survival Results from GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer   – Data presented at ASCO 2013 ...

Bristol-Myers Announces Phase I Data for Nivolumab and Yervoy

mia.burns Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients ...
Page 10 of 12« First...89101112
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS